Having said this, we also point to the challenges in GBM immunotherapy; an example is limited efficacy of a PD-1/PD-L1 checkpoint blockade [33], although targeting the PD-1/PD-L1 axis may still confer certain benefits [34]. This evidence concerns the gene CD274 and glioblastoma.